Case report: Bruton tyrosine kinase inhibitor as therapy for chronic lymphocytic leukemia infiltrating a kidney allograft [PDF]
The burden of chronic lymphocytic leukemia (CLL) in the prognosis of solid organ transplant (SOT) recipients seems non-negligible. Whether transplanting a patient with previous CLL is safe or what is the optimal monitoring and treatment management after ...
Louis Stavart +5 more
doaj +3 more sources
Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor [PDF]
Bruton tyrosine kinase (BTK) inhibitors have become an important therapy for untreated and previously treated patients with chronic lymphocytic leukemia (CLL).
Omar Alkharabsheh +3 more
doaj +3 more sources
A case of disseminated cryptococcal disease after Bruton tyrosine kinase inhibitor therapy: A brief review in the Australian context [PDF]
The use of Bruton tyrosine kinase (BTK) inhibitors for the treatment of a number of hematological conditions is rapidly increasing. Ibrutinib is the most clinically advanced and common BTK inhibitor currently utilized.
Nicholas Van Rooij, MD +3 more
doaj +3 more sources
Aplastic Anaemia in a Chronic Lymphocytic Leukaemia Patient Treated With Acalabrutinib, a Bruton Tyrosine Kinase Inhibitor—Case Report [PDF]
Introduction Although Immune cytopenias such as immune thrombocytopenia (ITP), autoimmune haemolytic anaemia (AIHA) and pure red blood cell aplasia (PRCA) are well documented associations with chronic lymphocytic leukaemia (CLL), aplastic anaemia (AA) is
Zachray Wei +3 more
doaj +2 more sources
Venetoclax Consolidation After Bruton Tyrosine Kinase Inhibitor Treatment for Patients With Chronic Lymphocytic Leukemia [PDF]
Introduction Bruton tyrosine kinase inhibitors (BTKi) are highly effective therapy for chronic lymphocytic leukemia (CLL) but can lead to long‐term side effects.
Benjamin Heyman +2 more
doaj +2 more sources
Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies [PDF]
Bruton tyrosine kinase (BTK) is a validated target for treatment of B-cell malignancies, and oral inhibitors of BTK have emerged as a standard of care for these diseases.
Hussein A. Abbas, William G. Wierda
doaj +2 more sources
Background Chronic lymphocytic leukaemia is the most common leukaemia subtype and associated with profound immunosuppression. Bruton Tyrosine Kinase inhibitors have revolutionised chronic lymphocytic leukaemia management; however, Bruton Tyrosine Kinase ...
Jonathan A Cook +16 more
doaj +2 more sources
Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma – A case report [PDF]
The use of Bruton's tyrosine kinase inhibitors (BTKi) is rapidly increasing for patients with mantle cell lymphoma (MCL). Side effects reported so far are usually manageable.
Anna Nikkarinen, Ingrid Glimelius
doaj +2 more sources
P1604: IMPACT OF THROMBOPOIETIN LEVEL ON PLATELET RESPONSE IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA TREATED WITH RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR [PDF]
David Kuter +4 more
doaj +2 more sources
P1696: ECONOMIC BURDEN IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR PATIENTS WITH ≥2 PRIOR LINES OF THERAPY INCLUDING A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I) [PDF]
Masoom Priyadarshini +5 more
doaj +2 more sources

